Your browser doesn't support javascript.
loading
Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis.
Li, Lun; Han, Dongdong; Wang, Xiaowei; Wang, Quan; Tian, Jinhui; Yao, Jia; Yuan, Liqin; Qian, Ke; Zou, Qiongyan; Yi, Wenjun; Zhou, Enxiang; Yang, Kehu.
Afiliación
  • Li L; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Han D; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
  • Wang X; Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Wang Q; Department of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, Xijing Hospital, Four Military Medical University, Xi'an, Shaanxi, China.
  • Tian J; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  • Yao J; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Yuan L; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Qian K; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zou Q; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Yi W; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zhou E; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Yang K; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Future Oncol ; 13(11): 1021-1034, 2017 May.
Article en En | MEDLINE | ID: mdl-28088868
ABSTRACT

AIM:

To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients.

METHODS:

PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis.

RESULTS:

49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before hazard ratio [HR] 2.29; 95% CI 1.42-3.69; after HR 2.24; 95% CI 1.82-2.75) and disease-free survival (DFS; before HR 1.54; 95% CI 1.23-1.95; after HR 2.08; 95% CI 1.83-2.37). Low/no reduction or increase might be associated with worse DFS (HR 2.13; 95% CI 1.51-3.02) and OS.

CONCLUSION:

Ki-67 before and after neoadjuvant chemotherapy, as well as the change could predict the prognosis for breast cancer patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_breast_cancer Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Antígeno Ki-67 Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Future Oncol Año: 2017 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_breast_cancer Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Antígeno Ki-67 Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Future Oncol Año: 2017 Tipo del documento: Article País de afiliación: China